PDGF receptors as cancer drug targets

Cancer Cell

Volumn 3, Issue 5, 2003, Pages 439-443

  Pietras, Kristian ^a   Sjöblom, Tobias ^a   Rubin, Kristofer ^b   Heldin, Carl Henrik ^a   Östman, Arne ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Sweden)

^b Box 582   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SUNITINIB; ANTINEOPLASTIC AGENT; LIGAND;

AUTOPHOSPHORYLATION; CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; COMPARTMENT MODEL; DIMERIZATION; GROWTH STIMULATION; HUMAN; MOLECULAR WEIGHT; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; STROMA; ANIMAL; BIOLOGICAL MODEL; DISEASE MODEL; DRUG ANTAGONISM; PHYSIOLOGY; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; HUMANS; LIGANDS; MODELS, BIOLOGICAL; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 0141486251     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00089-8     Document Type: Review

References (49)

1. Albanell J., Rojo F., Averbuch S., Feyereislova A., Mascaro J.M., Herbst R., LoRusso P., Rischin D., Sauleda S., Gee J., et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol. 20:2002;110-124.
2. Apperley J.F., Gardembas M., Melo J.V., Russell-Jones R., Bain B.J., Baxter E.J., Chase A., Chessells J.M., Colombat M., Dearden C.E., et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N. Engl. J. Med. 347:2002;481-487.
3. Baselga J., Rischin D., Ranson M., Calvert H., Raymond E., Kieback D.G., Kaye S.B., Gianni L., Harris A., Bjork T., et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. 20:2002;4292-4302.
4. Betsholtz C., Karlsson L., Lindahl P. Developmental roles of platelet-derived growth factors. Bioessays. 23:2001;494-507.
5. Buchdunger E., Zimmerman J., Mett H., Meyer T., Muller M., Druker B.J., Lydon N.B. Inhibition of the Abl protein tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56:1996;100-104.
6. Cao R., Bråkenhielm E., Li X., Pietras K., Widenfalk J., Östman A., Eriksson U., Cao Y. Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-αα and -αβ receptors. FASEB J. 16:2002;1575-1583.
7. Capdeville R., Buchdunger E., Zimmermann J., Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1:2002;493-502.
8. Clarke I.D., Dirks P.B. A human brain tumor-derived PDGFR-α deletion mutant is transforming. Oncogene. 22:2003;722-733.
9. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., Kutok J., Clark J., Galinsky I., Griffin J.D., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348:2003;1201-1214.
10. Cools J., Stover E.H., Boulton C.L., Gotlib J., Legare R.D., Amaral S.M., Curley D.P., Duclos N., Rowan R., Kutok J.L., et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. Cancer Cell. 3:(this issue):2003.
11. Coussens L.M., Tinkle C.L., Hanahan D., Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell. 103:2000;481-490.
12. Dai C., Celestino J.C., Okada Y., Louis D.N., Fuller G.N., Holland E.C. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev. 15:2001;1913-1925.
13. Fleming T.P., Saxena A., Clark W.C., Robertson J.T., Oldfield E.H., Aaronson S.A., Ali I.U. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res. 52:1992;4550-4553.
14. Forsberg K., Valyi-Nagy I., Heldin C.-H., Herlyn M., Westermark B. Platelet-derived growth factor (PDGF) in oncogenesis: Development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc. Natl. Acad. Sci. USA. 90:1993;393-397.
15. Golub T.R., Barker G.F., Lovett M., Gilliland D.G. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 77:1994;307-316.
16. Guo P., Hu B., Gu W., Xu L., Wang D., Huang H.J., Cavanee W.K., Cheng S.Y. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am. J. Pathol. 162:2003;1083-1093.
17. Heinrich M.C., Corless C.L., Duensing A., McGreevey L., Chen C.J., Joseph N., Singer S., Griffith D.J., Haley A., Town A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 299:2003;708-710.
18. Heldin C.-H., Östman A., Eriksson U. New members of the platelet-derived growth factor family of mitogens. Arch. Biochem. Biophys. 398:2002;284-290.
19. Hellström M., Kalén M., Lindahl P., Abramsson A., Betsholtz C. Role of PDGF-B and PDGFR-β in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development. 126:1999;3047-3055.
20. Hermanson M., Nistér M., Betsholtz C., Heldin C.-H., Westermark B., Funa K. Endothelial cell hyperplasia in human glioblastoma: Coexpression of mRNA for platelet-derived growh factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation. Proc. Natl. Acad. Sci. USA. 85:1988;7748-7752.
21. Heuchel R., Berg A., Tallquist M., Åhlén K., Reed R.K., Rubin K., Claesson-Welsh L., Heldin C.-H., Soriano P. Platelet-derived growth factor β receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3. kinase signaling. Proc. Natl. Acad. Sci. USA. 96:1999;11410-11415.
22. Jain R.K. Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 46:2001;149-168.
23. Kilic T., Alberta J.A., Zdunek P.R., Acar M., Iannarelli P., O'Reilly T., Buchdunger E., Black P.M., Stiles C.D. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 60:2000;5143-5150.
24. Kumabe T., Sohma Y., Kayama T., Yoshimoto T., Yamamoto T. Amplification of α-platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin. Oncogene. 7:1992;627-633.
25. LaRochelle W.J., Jeffers M., Corvalan J.R.F., Xiao-Chi Jia X.-C., Xiao Feng X., Sandra Vanegas S., Vickroy J.D., Yang X.-D., Chen F., Gazit G., et al. Platelet-derived Growth Factor D: Tumorigenicity in Mice and Dysregulated Expression in Human Cancer. Cancer Res. 62:2002;2468-2473.
26. Li H., Fredriksson L., Li X., Eriksson U. PDGF-D is a potent transforming and angiogenic growth factor. Oncogene. 22:2003;1501-1510.
27. Lokker N.A., Sullivan C.M., Hollenbach S.J., Israel M.A., Giese N.A. Platelet-derived Growth Factor (PDGF) Autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res. 62:2002;3729-3735.
28. Magnusson M.K., Meade K.E., Brown K.E., Arthur D.C., Krueger L.A., Barrett A.J., Dunbar C.E. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor β receptor in chronic myelomonocytic leukemia. Blood. 98:2001;2518-2525.
29. Magnusson M.K., Meade K.E., Nakamura R., Barrett J., Dunbar C.E. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor β receptor fusion oncogene. Blood. 100:2002;1088-1091.
30. Maki R.G., Awan R.A., Dixon R.H., Jhanwar S., Antonescu C.R. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int. J. Cancer. 100:2002;623-626.
31. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., Schreck R.E., Abrams T.J., Ngai T.J., Lee L.B., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9:2003;327-337.
32. O'Brien K.P., Seroussi E., Dal Cin P., Sciot R., Mandahl N., Fletcher J.A., Turc-Carel C., Dumanski J.P. Various regions within the α-helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant-cell fibroblastomas. Gene Chrom. Cancer. 23:1998;187-193.
33. Östman A., Heldin C.-H. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv. Cancer Res. 80:2001;1-38.
34. Pietras K., Östman A., Sjöquist M., Buchdunger E., Reed R.K., Heldin C.-H., Rubin K. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 61:2001;2929-2934.
35. Pietras K., Rubin K., Sjöblom T., Buchdunger E., Sjöquist M., Heldin C.-H., Östman A. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 62:2002;5476-5484.
36. Pietras K., Stumm M., Hubert M., Buchdunger E., Rubin K., Heldin C.-H., McSheehy P., Wartmann M., Östman A. STI571 enhances the therapeutic index of epithilone B (EPO906) by a tumor-selective increase of drug uptake. Clin. Cancer Res. in press:2003.
37. Risau W., Drexler H., Mironov V., Smits A., Siegbahn A., Funa K., Heldin C.-H. Platelet-derived growth factor is angiogenic in vivo. Growth Factors. 7:1992;261-266.
38. Rodt S.Å., Åhlén K., Berg A., Rubin K., Reed R.K. A novel physiological function for platelet-derived growth factor-BB in rat dermis. J. Physiol. 495:1996;193-200.
39. Rubin B.P., Schuetze S.M., Eary J.F., Norwood T.H., Mirza S., Conrad E.U., Bruckner J.D. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J. Clin. Oncol. 20:2002;3586-3591.
40. Shamah S.M., Stiles C.D., Guha A. Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells. Mol. Cell. Biol. 13:1993;7203-7212.
41. Shao Z.-M., Nguyen M., Barsky S.H. Human breast carcinoma desmoplasia is PDGF initiated. Oncogene. 19:2000;4337-4345.
42. Shimizu A., O'Brien K.P., Sjöblom T., Pietras K., Buchdunger E., Collins V.P., Heldin C.-H., Dumanski J.P., Östman A. The dermatofibrosarcoma protuberans-associated collagen type Iα1/platelet- derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. 59:1999;3719-3723.
43. Siegbahn A., Hammacher A., Westermark B., Heldin C.-H. Differential effects of the various isoforms of platelet-derived growth factor on chemotaxis of fibroblasts, monocytes, and granulocytes. J. Clin. Invest. 85:1990;916-920.
44. Simon M.-P., Pedeutour F., Sirvent N., Grosgeorge J., Minoletti F., Coindre J.-M., Terrier-Lacombe M.-J., Mandahl N., Craver R.D., Blin N., et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat. Genet. 15:1997;95-98.
45. Skobe M., Fusenig N.E. Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc. Natl. Acad. Sci. USA. 95:1998;1050-1055.
46. Strawn L.M., Mann E., Elliger S.S., Chu L.M., Germain L.L., Niederfellner G., Ullrich A., Shawver L.K. Inhibition of glioma cell growth by a truncated platelet-derived growth factor-β receptor. J. Biol. Chem. 269:1994;21215-21222.
47. Sundberg C., Ljungström M., Lindmark G., Gerdin B., Rubin K. Microvascular pericytes express platelet-derived growth factor-β receptors in human healing wounds and colorectal adenocarcinoma. Am. J. Pathol. 143:1993;1377-1388.
48. Uehara H., Kim S.J., Karashima T., Shepherd D.L., Fan D., Tsan R., Killion J.J., Logothetis C., Mathew P., Fidler I.J. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J. Natl. Cancer Inst. 95:2003;458-470.
49. Uhrbom L., Hesselager G., Nistér M., Westermark B. Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res. 58:1998;5275-5279.